Innovative formulation of microencapsulated "spirubiotic sachets" as a synbiotic treatment for metabolic syndrome patients.

Spirubiotic sachets were successfully formulated by combining microencapsulated Spirulina platensis (spray-dried with whey protein, coconut-flavored) and freeze-dried probiotic bacteria, and characterized physico-sensorially.

• Spirulina platensis was microencapsulated with whey protein using spray drying technology
• Probiotic bacteria were microencapsulated by freeze-drying
• HPLC analysis was performed on the Spirulina microcapsules
• Physico-sensory tests were conducted on the final spirubiotic sachet product
• The product was flavored with coconut taste for palatability

A clinical trial enrolled fifty diagnosed metabolic syndrome cases who received one spirubiotic sachet per day along with a tailored diet regimen for 3 months.

• Fifty (50) diagnosed metabolic syndrome cases were enrolled in the study
• Treatment duration was 3 months
• Patients received one spirubiotic sachet per day
• A tailored diet regimen was administered concurrently
• Pre- and post-treatment assessments included clinical, dietary, anthropometric, body composition, and biochemical parameters

Treatment with spirubiotic sachets resulted in decreased dietary caloric intake in metabolic syndrome patients.

• Pre- and post-treatment dietary assessments were conducted
• Decreased dietary calories were observed following the 3-month intervention
• The tailored diet regimen was administered alongside the spirubiotic sachet

Spirubiotic sachet treatment led to improved anthropometric measures and altered body composition in metabolic syndrome patients.

• Anthropometric data were collected pre- and post-treatment
• Body composition measurements were conducted pre- and post-treatment
• Improvements in anthropometric measures were reported after 3 months of treatment
• Metabolic syndrome is characterized by co-occurrence of obesity, among other conditions, suggesting weight-related parameters were among those improved

Biochemical parameters associated with metabolic syndrome, including hyperlipidemia and hyperglycemia markers, were normalized following spirubiotic sachet treatment.

• Enzymatic colorimetric methods and ELISA kits were used to assess biochemical parameters
• Parameters assessed included those related to hyperlipidemia, weight gain, hyperglycemia, and related problems
• Biochemical parameters were brought closer to normal levels after treatment
• The majority of metabolic abnormalities were effectively reversed
• Metabolic syndrome conditions targeted included dyslipidemia, hypertension, and type 2 diabetes-related parameters

Spirulina platensis and probiotic bacteria were found to work together synergistically in managing metabolic syndrome and related diseases.

• The combination product was referred to as a 'synbiotic' treatment
• Sp and Pb work together synergistically to help manage people with MeS and related diseases
• The synbiotic approach was deemed innovative with beneficial health effects
• Both components individually have been shown to have beneficial effects in controlling metabolic syndrome prior to this study